Go to
JCI Insight
Citations to this article
Hila Shaim, … , Amy B. Heimberger, Katayoun Rezvani
Published June 17, 2021
Citation Information: J Clin Invest. 2021;131(14):e142116. https://doi.org/10.1172/JCI142116.
Citation Information: J Clin Invest. 2021;131(14):e142116. https://doi.org/10.1172/JCI142116.
Abstract
Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs because glioblastoma stem cells (GSCs) are resistant to all standard therapies. We showed that GSCs, but not normal astrocytes, are sensitive to lysis by healthy allogeneic natural killer (NK) cells in vitro. Mass cytometry and single-cell RNA sequencing of primary tumor samples revealed that GBM tumor–infiltrating NK cells acquired an altered phenotype associated with impaired lytic function relative to matched peripheral blood NK cells from patients with GBM or healthy donors. We attributed this immune evasion tactic to direct cell-to-cell contact between GSCs and NK cells via αv integrin–mediated TGF-β activation. Treatment of GSC-engrafted mice with allogeneic NK cells in combination with inhibitors of integrin or TGF-β signaling or with TGFBR2 gene–edited allogeneic NK cells prevented GSC-induced NK cell dysfunction and tumor growth. These findings reveal an important mechanism of NK cell immune evasion by GSCs and suggest the αv integrin/TGF-β axis as a potentially useful therapeutic target in GBM.
Authors
Hila Shaim, Mayra Shanley, Rafet Basar, May Daher, Joy Gumin, Daniel B. Zamler, Nadima Uprety, Fang Wang, Yuefan Huang, Konrad Gabrusiewicz, Qi Miao, Jinzhuang Dou, Abdullah Alsuliman, Lucila N. Kerbauy, Sunil Acharya, Vakul Mohanty, Mayela Mendt, Sufang Li, JunJun Lu, Jun Wei, Natalie W. Fowlkes, Elif Gokdemir, Emily L. Ensley, Mecit Kaplan, Cynthia Kassab, Li Li, Gonca Ozcan, Pinaki P. Banerjee, Yifei Shen, April L. Gilbert, Corry M. Jones, Mustafa Bdiwi, Ana K. Nunez-Cortes, Enli Liu, Jun Yu, Nobuhiko Imahashi, Luis Muniz-Feliciano, Ye Li, Jian Hu, Giulio Draetta, David Marin, Dihua Yu, Stephan Mielke, Matthias Eyrich, Richard E. Champlin, Ken Chen, Frederick F. Lang, Elizabeth J. Shpall, Amy B. Heimberger, Katayoun Rezvani
Citation information
Citations to this article (142)
| Title and authors | Publication | Year |
|---|---|---|
|
Research Progress of NK Cells in Glioblastoma Treatment
Wu H, Liu Q, Wang F, Gao W, Zhou F, Zhao H |
OncoTargets and Therapy | 2025 |
|
In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma
Courot H, Rigal E, Adib N, Criton M, Cookson A, Fauvel B, Presumey J |
Cells | 2025 |
|
CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines
Look T, Sankowski R, Bouzereau M, Fazio S, Sun M, Buck A, Binder N, Mastall M, Prisco F, Seehusen F, Frei J, Wyss C, Snijder B, Nombela Arrieta C, Weller M, Pascolo S, Weiss T |
Cell Reports Medicine | 2025 |
|
TGF-β-mediated activation of fibroblasts in cervical cancer: implications for tumor microenvironment and prognosis
Qu H, Zhao J, Zuo X, He H, Wang X, Li H, Zhang K |
PeerJ | 2025 |
|
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression
Rea A, Santana-Hernández S, Villanueva J, Sanvicente-García M, Cabo M, Suarez-Olmos J, Quimis F, Qin M, Llorens E, Blasco-Benito S, Torralba-Raga L, Perez L, Bhattarai B, Alari-Pahissa E, Georgoudaki AM, Balaguer F, Juan M, Pardo J, Celià-Terrassa T, Rovira A, Möker N, Zhang C, Colonna M, Spanholtz J, Malmberg KJ, Montagut C, Albanell J, Güell M, López-Botet M, Muntasell A |
Nature Immunology | 2025 |
|
Reactive Astrocytes in Glioma: Emerging Opportunities and Challenges
Wu J, Li R, Wang J, Zhu H, Ma Y, You C, Shu K |
International Journal of Molecular Sciences | 2025 |
|
Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors.
Jiang Q, Yu W, Ma J, Zhao M, Zou J, Mir S, Zhang J, Germain RN, Hassan R |
Science advances | 2025 |
|
Engineering innate immune cells for cancer immunotherapy.
Tarannum M, Ding X, Barisa M, Hu S, Anderson J, Romee R, Zhang J |
Nature biotechnology | 2025 |
|
Head-to-head: IL-21 triumphs over IL-15 in NK cell therapy for glioblastoma.
Miller JC, Cao B, Shen J |
Acta biochimica et biophysica Sinica | 2025 |
|
TENT5A Increases Glioma Malignancy and Promotes its Progression.
Hu J, Zeng L, Hu R, Gong D, Liu M, Ding J |
Recent patents on anti-cancer drug discovery | 2025 |
|
Integrin signaling in tumor biology: mechanisms of intercellular crosstalk and emerging targeted therapies.
Li Y, Peng S, Xu J, Liu W, Luo Q |
PeerJ | 2025 |
|
Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment
Jiang D, Li Y |
Frontiers in Immunology | 2025 |
|
Prospects and applications of NK therapy in the treatment of gliomas (Review)
Liu Y, Su C, Wei X, Wei N, Qian Q, Xu Z |
Oncology Reports | 2025 |
|
The TGF-β Family in Glioblastoma.
Golán-Cancela I, Caja L |
International journal of molecular sciences | 2024 |
|
Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
Zang D, Dong Z, Liu Y, Chen Q |
BMC neurology | 2024 |
|
Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy.
Kudruk S, Forsyth CM, Dion MZ, Hedlund Orbeck JK, Luo J, Klein RS, Kim AH, Heimberger AB, Mirkin CA, Stegh AH, Artzi N |
Proceedings of the National Academy of Sciences | 2024 |
|
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia A, Tarannum M, Lérias JR, Piccinelli S, Borrego LM, Maeurer M, Romee R, Castillo-Martin M |
Cells | 2024 |
|
Current approaches in glioblastoma multiforme immunotherapy.
Aghajani M, Jalilzadeh N, Aghebati-Maleki A, Yari A, Tabnak P, Mardi A, Saeedi H, Aghebati-Maleki L, Baradaran B |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2024 |
|
Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.
Maia A, Tarannum M, Romee R |
Stem Cells Translational Medicine | 2024 |
|
Shedding light on function of long non-coding RNAs (lncRNAs) in glioblastoma
Hashemi M, Mousavian Roshanzamir S, Orouei S, Daneii P, Raesi R, Zokaee H, Bikarannejad P, Salmani K, Khorrami R, Deldar Abad Paskeh M, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M |
Non-coding RNA Research | 2024 |
|
Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.
Sabag B, Puthenveetil A, Levy M, Joseph N, Doniger T, Yaron O, Karako-Lampert S, Lazar I, Awwad F, Ashkenazi S, Barda-Saad M |
The EMBO Journal | 2024 |
|
Biosensor-Enhanced Organ-on-a-Chip Models for Investigating Glioblastoma Tumor Microenvironment Dynamics
Thenuwara G, Javed B, Singh B, Tian F |
Sensors (Basel, Switzerland) | 2024 |
|
No time to die: Epigenetic regulation of natural killer cell survival.
Hermans L, O'Sullivan TE |
Immunological Reviews | 2024 |
|
Non-Tumor Cells within the Tumor Microenvironment—The “Eminence Grise” of the Glioblastoma Pathogenesis and Potential Targets for Therapy
Bugakova AS, Chudakova DA, Myzina MS, Yanysheva EP, Ozerskaya IV, Soboleva AV, Baklaushev VP, Yusubalieva GM |
Cells | 2024 |
|
Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation
Du R, Tripathi S, Najem H, Brat DJ, Lukas RV, Zhang P, Heimberger AB |
Cells | 2024 |
|
Image‐based assessment of natural killer cell activity against glioblastoma stem cells
Du Y, Metcalfe S, Akunapuram S, Ghosh S, Spruck C, Richardson AM, Cohen\u2010Gadol AA, Shen J |
FEBS Open Bio | 2024 |
|
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.
Mohammad Taheri M, Javan F, Poudineh M, Athari SS |
Journal of Translational Medicine | 2024 |
|
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Shanley M, Daher M, Dou J, Li S, Basar R, Rafei H, Dede M, Gumin J, Garcίa JP, Cortes AK, He S, Jones CM, Acharya S, Fowlkes NW, Xiong D, Singh S, Shaim H, Hicks SC, Liu B, Jain A, Zaman MF, Miao Q, Li Y, Uprety N, Liu E, Muniz-Feliciano L, Deyter GM, Mohanty V, Zhang P, Evans SE, Shpall EJ, Lang FF, Chen K, Rezvani K |
Cancer cell | 2024 |
|
Endovascular surgical neuro-oncology: advancing a new subspecialty.
Young CC, Kan P, Chen SR, Lang FF |
Journal of neuro-oncology | 2024 |
|
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells.
Thangaraj JL, Coffey M, Lopez E, Kaufman DS |
Cell stem cell | 2024 |
|
Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme
Cooksey LC, Friesen DC, Mangan ED, Mathew PA |
Cells | 2024 |
|
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S |
Cellular and Molecular Immunology | 2024 |
|
Increased peritoneal TGF-β1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer.
Maas RJA, Hoogstad-van Evert JS, Hagemans IM, Brummelman J, van Ens D, de Jonge PKJD, Hooijmaijers L, Mahajan S, van der Waart AB, Hermans CKJC, de Klein J, Woestenenk R, van Herwaarden AE, Schaap NPM, Rezaeifard S, Tauriello DVF, Zusterzeel PLM, Ottevanger N, Jansen JH, Hobo W, Dolstra H |
Frontiers in immunology | 2024 |
|
Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma
Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, Hicks KA, Zhang JV, Zhang L, Xie C, Wang J, Wang T, Xu J, Fraietta JA, Binder ZA, Lin Z, O\u2019Rourke DM |
Molecular Therapy | 2024 |
|
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments
Kennedy PR, Arvindam US, Phung SK, Ettestad B, Feng X, Li Y, Kile QM, Hinderlie P, Khaw M, Huang RS, Kaufman M, Puchalska P, Russell A, Butler J, Abbott L, McClure P, Luo X, Lu QT, Blazar BR, Crawford PA, Lim J, Miller JS, Felices M |
Science Advances | 2024 |
|
Systematic multiomics analysis and in vitro experiments suggest that ITGA5 could serve as a promising therapeutic target for ccRCC.
Che X, Tian X, Wang Z, Zhu S, Ye S, Wang Y, Chen Y, Huang Y, Anwaier A, Yao P, Chen Y, Wu K, Liu Y, Xu W, Zhang H, Ye D |
Cancer cell international | 2024 |
|
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization
Chen S, Zhu H, Jounaidi Y |
Signal Transduction and Targeted Therapy | 2024 |
|
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.
Diorio C, Teachey DT, Grupp SA |
Nature reviews. Clinical oncology | 2024 |
|
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation
McCulloch TR, Rossi GR, Alim L, Lam PY, Wong JK, Coleborn E, Kumari S, Keane C, Kueh AJ, Herold MJ, Wilhelm C, Knolle PA, Kane L, Wells TJ, Souza-Fonseca-Guimaraes F |
Nature Communications | 2024 |
|
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA, Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang SC, Barkhoudarian G, Kelly DF, Juarez TM |
Oncoimmunology | 2024 |
|
TGFβ family signaling in human stem cell self-renewal and differentiation
Liu S, Ren J, Hu Y, Zhou F, Zhang L |
Cell Regeneration | 2024 |
|
CCN1 Promotes Mesenchymal Phenotype Transition Through Activating NF‐κB Signaling Pathway Regulated by S100A8 in Glioma Stem Cells
Guo X, Guo S, Tian F, Gao Z, Fan Y, Wang C, Xu S |
CNS Neuroscience & Therapeutics | 2024 |
|
The Emerging Role of Schwann Cells in the Tumor Immune Microenvironment and Its Potential Clinical Application
Zhang S, Chen J, Cheng F, Zheng F |
International Journal of Molecular Sciences | 2024 |
|
The innate defenders: a review of natural killer cell immunotherapies in cancer
Álvarez-Carrasco P, Maldonado-Bernal C |
Frontiers in Immunology | 2024 |
|
Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations
Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H |
Neuro-Oncology | 2024 |
|
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML
Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Cortes AK, Kaplan M, Acharya S, Shaim H, Xu AC, Wu M, Fang D, Banerjee PP, Garcia LM, Tiberti S, Lin P, Rafei H, Ensley E, Munir MN, Moore M, Shanley M, Mendt M, Kerbauy LN, Liu B, Biederstädt A, Gokdemir E, Ghosh S, Kundu K, Reyes-Silva F, Jiang XR, Wan X, Gilbert AL, Dede M, Mohanty V, Dou J, Zhang P, Liu E, Muniz-Feliciano L, Deyter GM, Jain AK, Rodriguez-Sevilla JJ, Colla S, Garcia-Manero G, Shpall EJ, Chen K, Abbas HA, Rai K, Rezvani K, Daher M |
Science translational medicine | 2024 |
|
Metabolic regulation of NK cell function: implications for immunotherapy
Sohn H, Cooper MA |
2023 | |
|
Natural Killer Cell-Based Immunotherapy against Glioblastoma
Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R |
International journal of molecular sciences | 2023 |
|
Advances in NK cell therapy for brain tumors
Fares J, Davis ZB, Rechberger JS, Toll SA, Schwartz JD, Daniels DJ, Miller JS, Khatua S |
npj Precision Oncology | 2023 |
|
B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression
Hou D, Castro B, Dapash M, Zolp A, Katz J, Arrieta V, Biermann J, Melms J, Kueckelhaus J, Benotmane J, Youngblood M, Rashidi A, Billingham L, Dmello C, Vazquez-Cervantes G, Lopez-Rosas A, Han Y, Patel R, Chia TY, Sun L, Prins R, Izar B, Heiland DH, Zhang P, Sonabend A, Miska J, Lesniak M, Zhao J, Lee-Chang C |
Research square | 2023 |
|
Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses
Moran J, Mylod E, Kane LE, Marion C, Keenan E, Mekhaeil M, Lysaght J, Dev KK, O\u2019Sullivan J, Conroy MJ |
Pharmaceutics | 2023 |
|
CAR immune cells: design principles, resistance and the next generation.
Labanieh L, Mackall CL |
Nature | 2023 |
|
Immunotargeting of Cancer Stem Cells
Köseer AS, Di Gaetano S, Arndt C, Bachmann M, Dubrovska A |
Cancers | 2023 |
|
Tumor microenvironment in glioblastoma: Current and emerging concepts
Sharma P, Aaroe A, Liang J, Puduvalli VK |
2023 | |
|
A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Chiu D, Qi J, Thin TH, Garcia-Barros M, Lee B, Hahn M, Mandeli J, Belani P, Nael K, Rashidipour O, Ghatan S, Hadjipanayis CG, Yong RL, Germano IM, Brody R, Tsankova NM, Gnjatic S, Kim-Schulze S, Hormigo A |
2023 | |
|
Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy
Yao S, Zhao L, Chen S, Wang H, Gao Y, Shao NY, Dai M, Cai H |
Frontiers in immunology | 2023 |
|
The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens
Mahajan S, Schmidt MH, Schumann U |
Cancers | 2023 |
|
CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway.
Mao XG, Xue XY, Lv R, Ji A, Shi TY, Chen XY, Jiang XF, Zhang X |
Cell Death and Disease | 2023 |
|
Disheveled3 enhanced EMT and cancer stem-like cells properties via Wnt/β-catenin/c-Myc/SOX2 pathway in colorectal cancer.
Li Z, Yang Z, Liu W, Zhu W, Yin L, Han Z, Xian Y, Wen J, Tang H, Lin X, Yang Y, Wang J, Zhang K |
Journal of Translational Medicine | 2023 |
|
Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
Shi Z, Wu Y, Zhuo Q, Zuo Y, Lin J, Shi H, Zhou H, Xu Z |
Scientific Reports | 2023 |
|
Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Chan MK, Chan EL, Ji ZZ, Chan AS, Li C, Leung KT, To KF, Tang PM |
2023 | |
|
Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.
Lazzarini E, Silvestris DA, Benvenuto G, Osti D, Fattore L, Paterra R, Finocchiaro G, Malatesta P, Daga A, Gallotti AL, Galli R, Pelicci G, Tesei A, Bedeschi M, Pallini R, Pasqualini L, Romualdi C, Gallo A, Ricci-Vitiani L, Indraccolo S |
Journal of Neuro-Oncology | 2023 |
|
ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experimental analysis.
Zheng X, Du Y, Liu M, Wang C |
Functional & Integrative Genomics | 2023 |
|
Barriers to overcoming immunotherapy resistance in glioblastoma.
Gillette JS, Wang EJ, Dowd RS, Toms SA |
Frontiers in Medicine | 2023 |
|
Glioblastoma heterogeneity at single cell resolution.
Eisenbarth D, Wang YA |
Oncogene | 2023 |
|
Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions
Wang M, Wang X, Jin X, Zhou J, Zhang Y, Yang Y, Liu Y, Zhang J |
Frontiers in immunology | 2023 |
|
Comprehensive analysis of angiogenesis pattern and related immune landscape for individual treatment in osteosarcoma.
Liao Z, Li M, Wen G, Wang K, Yao D, Chen E, Liang Y, Xing T, Su K, Liang C, Che Z, Ning Q, Tang J, Yan W, Li Y, Huang L |
npj Precision Oncology | 2023 |
|
CAR-NK cell therapy for glioblastoma: what to do next?
Xiong Q, Zhu J, Zhang Y, Deng H |
Frontiers in Oncology | 2023 |
|
Advanced T and Natural Killer Cell Therapy for Glioblastoma.
Yoon WS, Chung DS |
Journal of Korean Neurosurgical Society | 2023 |
|
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
Ascierto PA, Avallone A, Bifulco C, Bracarda S, Brody JD, Emens LA, Ferris RL, Formenti SC, Hamid O, Johnson DB, Kirchhoff T, Klebanoff CA, Lesinski GB, Monette A, Neyns B, Odunsi K, Paulos CM, Powell DJ Jr, Rezvani K, Segal BH, Singh N, Sullivan RJ, Fox BA, Puzanov I |
Journal of Translational Medicine | 2023 |
|
Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review
Budhiraja S, Najem H, Tripathi S, Wadhawani NR, Horbinski C, McCord M, Lenzen AC, Heimberger AB, DeCuypere M |
Cancers | 2023 |
|
The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma.
Sooreshjani M, Tripathi S, Dussold C, Najem H, de Groot J, Lukas RV, Heimberger AB |
Cancers | 2023 |
|
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, Noh JY |
Frontiers in immunology | 2023 |
|
Chimeric antigen receptor engineered natural killer cells for cancer therapy.
Zhang Y, Zhou W, Yang J, Yang J, Wang W |
Experimental Hematology and Oncology | 2023 |
|
Cancer stem cells in brain tumors: From origin to clinical implications
Lin S, Li K, Qi L |
2023 | |
|
NK cell-based tumor immunotherapy
Zhang H, Yang L, Wang T, Li Z |
Bioactive Materials | 2023 |
|
The Spectrum of Molecular Pathways in Gliomas—An Up-to-Date Review
Nafe R, Hattingen E |
Biomedicines | 2023 |
|
Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity
Nehama D, Woodell AS, Maingi SM, Hingtgen SD, Dotti G |
Neuro-Oncology | 2023 |
|
Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?
Giles B, Nakhjavani M, Wiesa A, Knight T, Shigdar S, Samarasinghe RM |
Cancers | 2023 |
|
The role of angiogenic growth factors in the immune microenvironment of glioma
Ge Z, Zhang Q, Lin W, Jiang X, Zhang Y |
Frontiers in Oncology | 2023 |
|
An immune‐related multi‐omics analysis of dolichyl‐diphosphooligosaccharide protein glycosyltransferase in glioma: Prognostic value exploration and competitive endogenous RNA network identification
Liu J, Feng C, Liu M, Zhou Y, Shen Y, Li J, Wei X |
IET Systems Biology | 2023 |
|
Naringenin ameliorates collagen‐induced arthritis through activating AMPK‐mediated autophagy in macrophages
Zhang W, Zhang Y, Zhang J, Deng C, Zhang C |
Immunity, Inflammation and Disease | 2023 |
|
Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma
Srivastava R, Dodda M, Zou H, Li X, Hu B |
Antioxidants & Redox Signaling | 2023 |
|
Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment
Portillo AL, Monteiro JK, Rojas EA, Ritchie TM, Gillgrass A, Ashkar AA |
Frontiers in immunology | 2023 |
|
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Wang Y, Jin S, Zhuang Q, Liu N, Chen R, Adam SA, Jin J, Sun J |
2023 | |
|
The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma.
Liu Z, Wang S, Yu K, Chen K, Zhao L, Zhang J, Dai K, Zhao P |
Journal of Translational Medicine | 2023 |
|
Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments
Lee S, Kim TD |
International journal of molecular sciences | 2023 |
|
Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients
Zimmer N, Trzeciak ER, Müller A, Licht P, Sprang B, Leukel P, Mailänder V, Sommer C, Ringel F, Tuettenberg J, Kim E, Tuettenberg A |
Cancers | 2023 |
|
Unlocking Glioblastoma Secrets: Natural Killer Cell Therapy against Cancer Stem Cells
Du Y, Pollok KE, Shen J |
Cancers | 2023 |
|
Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma
Tan AK, Henry A, Goffart N, van Logtestijn S, Bours V, Hol EM, Robe PA |
Cancers | 2023 |
|
Identification of prognostic risk score of disulfidptosis-related genes and molecular subtypes in glioma
Jiang Q, Ling GY, Yan J, Tan JY, Nong RB, Li JW, Deng T, Mo LG, Huang QR |
Biochemistry and Biophysics Reports | 2023 |
|
Harnessing natural killer cell effector function against cancer.
Blunt MD, Khakoo SI |
2023 | |
|
Current status and future perspective of natural killer cell therapy for cancer
Zhao X, Lin M, Huang X |
2023 | |
|
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Friedman JS, Jun T, Rashidipour O, Huang KL, Ellis E, Kadaba P, Belani P, Nael K, Tsankova NM, Sebra R, Hormigo A |
Cancer Immunology, Immunotherapy | 2023 |
|
Emerging Biomarkers for Immunotherapy in Glioblastoma
N Mensali, E Inderberg |
Cancers | 2022 |
|
Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
J Park, H Lee |
Cancers | 2022 |
|
The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?
L da Silva, L Catharino, V da Silva, G Evangelista, J Barbuto |
Biomedicines | 2022 |
|
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
D Kreatsoulas, C Bolyard, B Wu, H Cam, P Giglio, Z Li |
Journal of Hematology & Oncology | 2022 |
|
The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis
Chen B, Mu C, Zhang Z, He X, Liu X |
Frontiers in immunology | 2022 |
|
Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
Niedbała M, Malarz K, Sharma G, Kramer-Marek G, Kaspera W |
OncoTargets and therapy | 2022 |
|
Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma
Eisemann T, Wechsler-Reya RJ |
Genes & development | 2022 |
|
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi S, Sharabi A |
Pharmacology & Therapeutics | 2022 |
|
Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
Gemelli M, Noonan DM, Carlini V, Pelosi G, Barberis M, Ricotta R, Albini A |
Frontiers in Oncology | 2022 |
|
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Ran GH, Lin YQ, Tian L, Zhang T, Yan DM, Yu JH, Deng YC |
Signal Transduction and Targeted Therapy | 2022 |
|
Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma
Wang M, Zhou Z, Wang X, Zhang C, Jiang X |
Cell Death and Disease | 2022 |
|
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski TJ, Biederstädt A, Rezvani K |
Nature reviews. Cancer | 2022 |
|
The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics
Rivera-Caraballo KA, Nair M, Lee TJ, Kaur B, Yoo JY |
2022 | |
|
Mechanical Properties of the Extracellular Environment of Human Brain Cells Drive the Effectiveness of Drugs in Fighting Central Nervous System Cancers
Cieśluk M, Pogoda K, Piktel E, Wnorowska U, Deptuła P, Bucki R |
Brain Sciences | 2022 |
|
Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands.
Zhong J, Yang X, Chen J, He K, Gao X, Wu X, Zhang M, Zhou H, Xiao F, An L, Wang X, Shi Y, Zhang N |
Nature Communications | 2022 |
|
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri A, García-Ortiz A, Castellano E, Córdoba L, Maroto-Martín E, Encinas J, Leivas A, Río P, Martínez-López J |
Frontiers in immunology | 2022 |
|
Next Steps for Immunotherapy in Glioblastoma
Cao TQ, Wainwright DA, Lee-Chang C, Miska J, Sonabend AM, Heimberger AB, Lukas RV |
Cancers | 2022 |
|
Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Drakulic D, Schwirtlich M, Petrovic I, Mojsin M, Milivojevic M, Kovacevic-Grujicic N, Stevanovic M |
Cells | 2022 |
|
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
Seliger B, Koehl U |
Frontiers in immunology | 2022 |
|
Advanced Cell Therapies for Glioblastoma.
Wang G, Wang W |
Frontiers in immunology | 2022 |
|
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
Liu G, Qiu Y, Zhang P, Chen Z, Chen S, Huang W, Wang B, Yu X, Guo D |
Pharmaceutics | 2022 |
|
Regulatory pattern of abnormal promoter CpG island methylation in the glioblastoma multiforme classification
Wang R, Zhao L, Wang S, Zhao X, Liang C, Wang P, Li D |
Frontiers in Genetics | 2022 |
|
The Next Generation of Cellular Immunotherapy: CAR-NK Cells
Moscarelli J, Zahavi D, Maynard R, Weiner L |
2022 | |
|
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Zhao Y, Bai Y, Shen M, Li Y |
Frontiers in immunology | 2022 |
|
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza-Valderrey A, Alvarez M, De Maria A, Margolin K, Melero I, Ascierto ML |
Cells | 2022 |
|
Transcriptome Analysis Identifies Accumulation of Natural Killer Cells with Enhanced Lymphotoxin-β Expression during Glioblastoma Progression
Monaco G, Khavaran A, Gasull AD, Cahueau J, Diebold M, Chhatbar C, Friedrich M, Heiland DH, Sankowski R |
Cancers | 2022 |
|
Natural killer cell immunotherapy in glioblastoma.
Hosseinalizadeh H, Habibi Roudkenar M, Mohammadi Roushandeh A, Kuwahara Y, Tomita K, Sato T |
2022 | |
|
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
Wu X, Matosevic S |
2022 | |
|
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
Xiao J, Zhang T, Gao F, Zhou Z, Shu G, Zou Y, Yin G |
Cancers | 2022 |
|
The role of CXCR3 and its ligands in cancer
Wang X, Zhang Y, Wang S, Ni H, Zhao P, Chen G, Xu B, Yuan L |
Frontiers in Oncology | 2022 |
|
Multiplexed engineering and precision gene editing in cellular immunotherapy
Biederstädt A, Manzar GS, Daher M |
Frontiers in immunology | 2022 |
|
Single‐Cell Transcriptome Identifies Drug‐Resistance Signature and Immunosuppressive Microenvironment in Metastatic Small Cell Lung Cancer
Zhang J, Zhang H, Zhang L, Li D, Qi M, Zhang L, Yu H, Wang D, Jiang G, Wang X, Zhu X, Zhang P |
2022 | |
|
Allogeneic natural killer cell therapy
Berrien-Elliott MM, Jacobs MT, Fehniger TA |
Blood | 2022 |
|
Comparable TGF-β mediated immune suppression in ex vivo expanded NK cells from cord blood and peripheral blood: implications for adoptive immunotherapy
Chaudhry K, Dowlati E, Long MD, Geiger A, Lang H, Gomez EC, Muniraj N, Sanchez CE, Singh PK, Liu S, Bollard CM, Cruz CR |
Cytotherapy | 2022 |
|
Advances in Immunotherapy for Adult Glioblastoma
CR Chokshi, BA Brakel, N Tatari, N Savage, SK Salim, C Venugopal, SK Singh |
Cancers | 2021 |
|
Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies
N Attia, M Mashal, S Pemminati, A Omole, C Edmondson, W Jones, P Priyadarshini, T Mughal, P Aziz, B Zenick, A Perez, M Lacken |
Cells | 2021 |
|
Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment
J Wei, E Gilboa, GA Calin, AB Heimberger |
Frontiers in Oncology | 2021 |
|
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
C Zalfa, S Paust |
Frontiers in immunology | 2021 |
|
Leveraging NKG2D Ligands in Immuno-Oncology
MB Fuertes, CI Domaica, NW Zwirner |
Frontiers in immunology | 2021 |
|
Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids
T Morimoto, T Nakazawa, R Matsuda, F Nishimura, M Nakamura, S Yamada, I Nakagawa, YS Park, T Tsujimura, H Nakase |
Cancers | 2021 |
|
MT1-MMP Cooperates with TGF-β Receptor-Mediated Signaling to Trigger SNAIL and Induce Epithelial-to-Mesenchymal-like Transition in U87 Glioblastoma Cells
S Djediai, NG Suarez, LE Cheikh-Hussein, SR Torres, L Gresseau, S Dhayne, Z Joly-Lopez, B Annabi |
International journal of molecular sciences | 2021 |
|
The immune landscape of common CNS malignancies: implications for immunotherapy
M Ott, RM Prins, AB Heimberger |
Nature Reviews Clinical Oncology | 2021 |
|
Engineering the next generation of CAR-NK immunotherapies
A Biederstädt, K Rezvani |
International Journal of Hematology | 2021 |
|
Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
VS Arnesen, AG Navarro, M Chekenya |
Cancers | 2021 |
|
Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies
F St-Pierre, S Bhatia, S Chandra |
Cancers | 2021 |
|
Immunometabolic consequences of IL-23
S Allison |
Nature Reviews Nephrology | 2021 |
|
De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma
A Maruyama, Y Sato, J Nakayama, J Murai, T Ishikawa, T Soga, H Makinoshima |
Scientific Reports | 2021 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)